This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gneiss, C Articles by Deisenhammer, F Search for Related Content PubMed PubMed Citation Articles by Gneiss, C Articles by Deisenhammer, F Social Bookmarking                         What's this?

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

P Tripp

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

F Reichartseder

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

R Egg

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

R Ehling

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

A Lutterotti

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

M Khalil

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

B Kuenz

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

I Mayringer

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

M Reindl

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

T Berger

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria

F Deisenhammer

Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria, florian.deisenhammer{at}uibk.ac.at

Interferon beta (IFNß) is a first-line therapy for multiple sclerosis (MS). However, some patients experience a decline in efficacy with continued therapy due to the development of anti-IFNß neutralizing antibodies (NAb). We investigated the frequency of NAb cross-sectionally in 846 MS patients who were receiving IFNß-1b, IFNß-1a im, or IFNß-1a sc. The frequency of NAb in patients receiving IFNß-1a im was lower (5%) than in patients treated with any other form of IFNß (22-35%) (P < 0.0001). Binding antibodies (BAb) were measured in 808 patients. The frequency differed significantly between treatment groups, ranging from 45% (IFNß-1a im) to 88% (IFNß-1b). The proportion of NAb-positive patients within the BAb-positive group differed significantly among treatment groups, ranging between 12% (IFNß-1a im) and 51% (IFNß-1a sc). The median NAb titer from all IFNß-1a-treated patients was higher than from IFNß-1b-treated patients (446 versus 171 NU/mL, P = 0.04). Among NAb-positive patients, the frequency of NAb titers > 100 NU/mL was 71% for IFNß-1a compared with 58% for IFNß-1b (P = 0.04). Except for conflicting data regarding IFNß-1a sc, the results are generally consistent with the literature and together with the differing proportion of NAb-positive patients within the BAb-positive group, provide further insight into the immunogeni-city of the IFNß preparations.

Key Words: antibody titer • IFNß-1a • IFNß-1b • myxovirus A bioassay • neutralizing antibodies • relapsing-remitting multiple sclerosis

Multiple Sclerosis, Vol. 12, No. 6, 731-737 (2006)
DOI: 10.1177/1352458506070941


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Gneiss, P.-M. Koudouovoh-Tripp, S. Ropele, T. Gotwald, R. Ehling, A. Lutterotti, F. Aichner, G. Ladurner, C. Eggers, F. Schautzer, et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study Multiple Sclerosis, December 1, 2009; 15(12): 1481 - 1488. [Abstract] [PDF]

				M. Comabella, J. D. Lunemann, J. Rio, A. Sanchez, C. Lopez, E. Julia, M. Fernandez, L. Nonell, M. Camina-Tato, F. Deisenhammer, et al. A type I interferon signature in monocytes is associated with poor response to interferon-{beta} in multiple sclerosis Brain, December 1, 2009; 132(12): 3353 - 3365. [Abstract] [Full Text] [PDF]

				N Koch-Henriksen, P. Sorensen, K Bendtzen, and E. Flachs The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 601 - 605. [Abstract] [PDF]

				P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]

				C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer Comparative study of four different assays for the detection of binding antibodies against interferon-{beta} Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836. [Abstract] [PDF]